Amgen’s Lumakras Faces Full Approval Delay as FDA Requests New Study
The US Food and Drug Administration (FDA) has declined to grant full approval for Amgen’s...
China’s NMPA Proposes Enhanced IT and Visualization Requirements for Blood Product GMP
The National Medical Products Administration (NMPA) of China is currently soliciting public feedback on the...
Fresenius Medical Care Expands Dialysis Solutions in China with 6008 CARESystem Launch
Fresenius Medical Care AG has announced the official launch of its 6008 CARESystem hemodialysis filtration...
China Charts Course for Advanced Disease Prevention and Control System by 2030
China’s State Council has issued the “Guiding Opinions on Promoting the High Quality Development of...
Innovent Biologics Partners with Sanegene Bio USA to Develop Hypertension Drug
China-based Innovent Biologics (HKG: 1801) has entered into a partnership with Sanegene Bio USA Inc....
Guangdong Zhongsheng Pharmaceutical’s ZSP1273 for Influenza A Accepted for Review by NMPA
Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a Chinese pharmaceutical company, has announced that China’s...
Konruns Pharmaceutical Receives NMPA Go-Ahead for KC1036 Esophageal Cancer Study
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has received approval from the National Medical Products...
Jianzhijia Health-Chain to Purchase Local Drug Retailer for $23.5 Million
Yunnan Jianzhijia Health-Chain Co, Ltd (SHA: 605266), a Chinese healthcare company, has announced plans to...
Simcere Affiliate Shanghai Simnova Biotech Gets China Nod for CAR-T Therapy SNC109
Shanghai Simnova Biotech Co., Ltd, known as Simnova outside of China and an affiliate of...
Biocytogen and Lepu Biotechnology Develop WT1-Targeted Trispecific Antibody for Cancer Treatment
Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) and Lepu Biotechnology Co., Ltd (HKG: 2157) have...
Aidea Pharmaceutical Co. Terminates ACC006 Technology Transfer Deal with Lixin Bio
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has resolved to terminate its technology transfer agreement...
AstraZeneca to Acquire China’s Gracell Biotechnologies in $1.2 Billion Deal
Pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced its intention to fully acquire Gracell Biotechnologies...
China’s NHC Releases Third List of Recommended Generic Drugs for Development
The National Health Commission (NHC) of China has released its third list of drugs recommended...
FDA Grants Priority Review to MSD and Daiichi Sankyo’s ADC for Lung Cancer
The US Food and Drug Administration (FDA) has accepted under priority review a filing from...
AbbVie and Alpine Immune Sciences Halt Early Enrollment in Lupus Trial
AbbVie (NYSE: ABBV) and Alpine Immune Sciences (SWX: ALPN) have made the decision to prematurely...
Jiangsu Province Announces Dual Channel Management and Separate Payment Drug List
Jiangsu province’s healthcare security administration has released a list identifying drugs subject to dual channel...
J&J’s Rybrevant-Lazertinib Combo Accepted for FDA Review in NSCLC
The US Food and Drug Administration (FDA) has accepted for review Johnson & Johnson’s (J&J;...
Hunan Province Releases “Dual Channel” Drug Payment List with 226 Products
The Hunan Healthcare Security Administration has published a list of 226 drugs to be included...
Shanghai Fosun to Exclusively Commercialize Generic Entresto in China
Nanjing F&S Pharmatech Co., Ltd has officially launched its generic version of Novartis’s heart failure...
Shouyao Holdings Receives Ethical Approval for Phase III Study of ALK Inhibitor SY-3505
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) has announced that it has received ethical...